Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse
|Published in||Journal of biological response modifiers. 1989, vol. 8, no. 4, p. 366-374|
|Abstract||New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.|
|Keywords||Animals — Autoantibodies — Disease Models, Animal — Dose-Response Relationship, Drug — Female — Flow Cytometry — Fluorescent Antibody Technique — Glycoproteins/blood — Hematologic Tests — Immunoglobulins/analysis — Interleukin-2/administration & dosage/ therapeutic use — Lupus Erythematosus, Systemic/ drug therapy/mortality — Male — Mice — Recombinant Proteins/administration & dosage/therapeutic use|
This document has no fulltext available yet, but you can contact its author by using the form below.
|OWEN, K. L. et al. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse. In: Journal of biological response modifiers, 1989, vol. 8, n° 4, p. 366-374. https://archive-ouverte.unige.ch/unige:10954|